▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #630 by analyst upside · 2026-09-27
SLDB
Solid Biosciences Inc.
Healthcare · Market Cap $782M · P/E 0x
ANALYST PRICE TARGET
+155.4%
implied upside to consensus target
Current Price $7.29
Consensus Target $18.62
Bull Target $26.0
Bear Target $11.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
8
Hold
0
Sell
0
52-Week Low $3.79
52-Week High $11.45
YTD Return +33.8%
FUNDAMENTALS
Market Cap $782M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.89
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.79
52-Week High $11.45
Current Price $7.29
Bear Target $11.0
Bull Target $26.0
● Now $7.29 ● Target $18.62
TRADING DATA
Avg Volume 1.2M
YTD Return +33.8%
Analyst Count 13
Consensus Buy
Upside to Target +155.4%
Last Updated 2026-09-27

ANALYST SUMMARY

Solid Biosciences Inc. (SLDB) is currently trading at $7.29 with a Wall Street consensus price target of $18.62, implying potential upside of 155.4% over the next 12 months. 13 analysts currently cover SLDB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

SLDB operates in the Healthcare sector with a market capitalisation of $782M. The stock is up 33.8% year-to-date and is currently trading near the lower end of its 52-week range of $3.79 – $11.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SLDB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital ● Initiated
Outperform 2026-09-16 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-14 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-08-27 40% win rate (10 calls)
Truist Securities - Reiterated
Buy → Buy 2026-08-21 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-03 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-05-18 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-13 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →